^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ER (Estrogen receptor)

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    17h
    A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Hoffmann-La Roche | N=44 --> 80 | Trial completion date: Dec 2030 --> Feb 2030
    Enrollment change • Trial completion date • Trial initiation date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation
    |
    Kisqali (ribociclib) • fulvestrant • Itovebi (inavolisib)
    21h
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    24h
    Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=13, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    capecitabine • Libtayo (cemiplimab-rwlc)
    1d
    A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy (clinicaltrials.gov)
    P=N/A, N=30, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • EGFR positive
    1d
    TRIFOUR: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. (clinicaltrials.gov)
    P1/2, N=117, Active, not recruiting, Cantargia AB | Trial primary completion date: Jun 2025 --> Apr 2026
    Trial primary completion date • BRCA Companion diagnostic • PARP Companion diagnostic
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation
    |
    PD-L1 IHC 22C3 pharmDx • Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    carboplatin • gemcitabine • nadunolimab (CAN04)
    1d
    Genetic and Molecular Mechanisms Linking Breast Cancer to Meningioma Risk: Roles of EXO1, BRCA2, and ESR1. (PubMed, Curr Med Chem)
    This study provides genetic and functional evidence linking breast cancer to meningioma risk through DNA repair and hormonal pathways, supporting early risk assessment and targeted therapies to improve patient outcomes.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA2 (Breast cancer 2, early onset) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    azacitidine
    1d
    Phytochemicals Targeting Wnt/β-Catenin in Osteoblasts: Mechanisms, Scaffolds, and Computational Insights for Bone Therapeutics. (PubMed, Phytother Res)
    Structure-activity analyses identify flavanone glycosides and triterpenoids as promising scaffolds for medicinal chemistry optimization. Challenges, including poor bioavailability and off-target effects, necessitate advanced delivery systems and computational modeling to enhance selectivity and therapeutic utility, positioning these phytochemicals as viable leads for bone-related disorder treatments.
    Review • Journal
    |
    ER (Estrogen receptor) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    1d
    Tamoxifen differentially modulates endometrial hyperplasia via wild-type and mutant p53 regulation of the ALKBH5-REG1A axis. (PubMed, Front Oncol)
    These findings establish a mechanistic link between hormonal signaling, p53 allelic status, and m6A-dependent post-transcriptional regulation. Although further in vivo validation is required, disruption of the ALKBH5-REG1A axis may contribute to heterogeneous endometrial responses to tamoxifen, thereby providing a conceptual framework for biomarker-oriented investigation.
    Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • REG1A (Lithostathine-1-alpha) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    |
    TP53 mutation • ER positive • TP53 wild-type
    |
    tamoxifen
    1d
    Auditing shortcut learning and misclassification in artificial intelligence-based breast cancer genomic subtyping. (PubMed, JAMIA Open)
    The pseudo-SHAP method provides a scalable, interpretable auditing framework for detecting shortcut learning in resource-constrained environments. Its application could enhance transparency and equity in AI models for precision oncology.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • HER-2 elevation
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    1d
    Epigallocatechin promotes megakaryocyte differentiation via ERα-dependent SRC/PI3K/AKT signaling for thrombocytopenia treatment. (PubMed, J Ethnopharmacol)
    EGC promotes megakaryocyte differentiation via ERα-mediated activation of the SRC/PI3K/AKT pathway and subsequent regulation of hematopoietic transcription factors for the treatment of thrombocytopenia.
    Journal
    |
    ER (Estrogen receptor)
    3d
    PARK7 (DJ-1) indicates favorable prognosis and correlates with estrogen-receptor status and Nε-carboxymethyl-lysine (CML) accumulation in breast cancer. (PubMed, Cancer Treat Res Commun)
    In conclusion, PARK7 protein expression was associated with AGE accumulation and favorable prognosis in ductal breast cancer suggesting a possible application as biomarker. Further research is needed to understand the molecular mechanisms of gene regulation and function of the PARK7 protein in breast cancer.
    Journal
    |
    ER (Estrogen receptor)
    3d
    Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. (PubMed, Br J Cancer)
    We identified a subset of luminal breast cancers characterised by nuclear FGF2, AR upregulation, and PR isoform imbalance. Dual AR and Wnt pathway targeting may offer a promising strategy for antiprogestin-resistant disease.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor) • FGF2 (Fibroblast Growth Factor 2)